+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Treatment of Blastic-Phase CML Market by Treatment Type, Therapy Line, Mechanism of Action, Route of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
Treatment of Blastic-Phase CML Market by Treatment Type, Therapy Line, Mechanism of Action, Route of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

Treatment of Blastic-Phase CML Market by Treatment Type, Therapy Line, Mechanism of Action, Route of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6085417
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Chronic Myeloid Leukemia (CML) in its blastic phase poses significant challenges for patient care and commercial strategy due to its aggressive progression and evolving treatment landscape. Senior decision-makers must navigate a rapidly transforming space shaped by therapeutic advancements, shifting regulatory frameworks, and complex supply chain demands.

Market Snapshot: Blastic-Phase CML Landscape

The global blastic-phase CML market is experiencing a dynamic shift, driven by advances in molecular profiling, precision medicine, and the introduction of next-generation therapies. Decision-makers face increasing complexity as emerging innovative agents and resistance mechanisms reshape patient management pathways. Strategic planning now requires alignment with growing regulatory oversight and the imperative for real-world evidence to demonstrate both clinical efficacy and safety for high-risk patient populations.

Scope & Segmentation of the Blastic-Phase CML Market

This report delivers in-depth segmentation and analysis across the following core dimensions:

  • Treatment Types: Combination therapies, monoclonal antibodies, small molecule inhibitors
  • Therapy Lines: First line, second line, third line and beyond therapies
  • Mechanisms of Action: Bcr-Abl inhibitors, chemotherapy agents, immunomodulators
  • Routes of Administration: Intravenous and oral formulations
  • End Users: Ambulatory surgical centers, hospitals, specialty clinics
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy
  • Patient Age Groups: Adults, pediatrics
  • Regions Covered: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (e.g., United Kingdom, Germany, France, Russia, UAE, South Africa), Asia-Pacific (e.g., China, India, Japan, Australia, South Korea, Indonesia)
  • Companies Profiled: Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Viatris Inc., Sandoz International GmbH, Lupin Limited, Hikma Pharmaceuticals PLC

Key Takeaways for Senior Decision-Makers

  • Precision medicine is advancing patient stratification, allowing therapies to be tailored based on molecular subtypes identified through sophisticated profiling.
  • Combination therapies and immunomodulatory agents are gaining traction as innovations target resistance mechanisms unique to blastic-phase CML.
  • End-user needs vary significantly; hospitals prioritize intensive care and rapid intervention, while specialty clinics excel in ongoing disease management and adherence support.
  • Digital health tools are optimizing patient monitoring and response assessment, supporting data-informed adjustments to therapeutic regimens.
  • Regional disparities impact market access, with robust infrastructure in North America and parts of Asia-Pacific enabling faster adoption of novel agents, while developing regions address challenges through public-private partnerships and capacity building.

Tariff Impact: 2025 Supply Chain and Access Implications

Revised United States tariff policies for 2025 are directly affecting pharmaceutical supply chains by increasing production costs for blastic-phase CML therapies. Manufacturers are responding by localizing supply chains, strengthening partnerships with regional suppliers, and leveraging technology-driven visibility tools to reduce tariffs’ disruptive effects. These strategies aim to stabilize drug availability and maintain patient access despite fluctuating trade regulations. Organizations adopting collaborative procurement and diversified sourcing models are positioned to sustain operational continuity and manage upward pricing pressures.

Methodology & Data Sources

This research integrates proprietary primary interviews with hematologists, pharmaceutical executives, and key opinion leaders, alongside rigorous secondary review of clinical trial records, regulatory filings, and peer-reviewed literature. Data validation is accomplished via triangulation and advanced analytics to ensure reliability and actionable insights.

Why This Report Matters for CML Market Leaders

  • Enables data-backed strategic decisions by providing a comprehensive overview of treatment innovations, competitive intelligence, and real-world trends.
  • Supports resource allocation and commercial planning through segment analysis and regional insights tied to the latest regulatory, reimbursement, and supply chain environments.
  • Helps align clinical development goals with payer priorities and patient needs amid a shifting policy and technology landscape.

Conclusion

The blastic-phase CML market is entering a period of profound change as new therapies, digital tools, and supply strategies redefine stakeholder priorities. Informed decision-making and cross-functional collaboration are essential for improving patient outcomes and realizing commercial potential in this evolving landscape.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Real-world evidence on tyrosine kinase inhibitor resistance and management in blastic-phase CML
5.2. Emergence of allosteric inhibitors like asciminib offering new salvage options in blastic-phase CML
5.3. Integration of next-generation sequencing-based minimal residual disease monitoring for treatment personalization in blastic-phase CML
5.4. Clinical development of BCL-2 inhibitor combinations with TKIs to overcome resistance in blastic-phase CML
5.5. Evaluation of bispecific T-cell engager therapies targeting BCR-ABL and CD3 for refractory blastic-phase CML
5.6. Advancements in CAR T-cell therapy approaches for targeting Ph chromosome-positive blastic-phase CML
5.7. Combining allogeneic stem cell transplantation with novel targeted agents to improve outcomes in blastic-phase CML
5.8. Assessment of antibody-drug conjugates against CD33 and CD123 in myeloid blastic-phase CML treatment pipelines
5.9. Impact of checkpoint inhibitor immunotherapies in combination with TKIs for resistant blastic-phase CML cases
5.10. Role of personalized medicine through comprehensive genomic profiling to guide second-line therapy in blastic-phase CML
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Treatment of Blastic-Phase CML Market, by Treatment Type
8.1. Introduction
8.2. Combination Therapies
8.3. Monoclonal Antibodies
8.4. Small Molecule Inhibitors
9. Treatment of Blastic-Phase CML Market, by Therapy Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line and Beyond
10. Treatment of Blastic-Phase CML Market, by Mechanism of Action
10.1. Introduction
10.2. Bcr-Abl Inhibitors
10.3. Chemotherapy Agents
10.4. Immunomodulators
11. Treatment of Blastic-Phase CML Market, by Route of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
12. Treatment of Blastic-Phase CML Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Treatment of Blastic-Phase CML Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Treatment of Blastic-Phase CML Market, by Patient Age Group
14.1. Introduction
14.2. Adults
14.3. Pediatrics
15. Americas Treatment of Blastic-Phase CML Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Treatment of Blastic-Phase CML Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Treatment of Blastic-Phase CML Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novartis AG
18.3.2. Bristol-Myers Squibb Company
18.3.3. Pfizer Inc.
18.3.4. Takeda Pharmaceutical Company Limited
18.3.5. Sun Pharmaceutical Industries Limited
18.3.6. Teva Pharmaceutical Industries Limited
18.3.7. Viatris Inc.
18.3.8. Sandoz International GmbH
18.3.9. Lupin Limited
18.3.10. Hikma Pharmaceuticals PLC
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. TREATMENT OF BLASTIC-PHASE CML MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. TREATMENT OF BLASTIC-PHASE CML MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. TREATMENT OF BLASTIC-PHASE CML MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. TREATMENT OF BLASTIC-PHASE CML MARKET: RESEARCHAI
FIGURE 30. TREATMENT OF BLASTIC-PHASE CML MARKET: RESEARCHSTATISTICS
FIGURE 31. TREATMENT OF BLASTIC-PHASE CML MARKET: RESEARCHCONTACTS
FIGURE 32. TREATMENT OF BLASTIC-PHASE CML MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TREATMENT OF BLASTIC-PHASE CML MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 93. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 94. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 95. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 96. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 97. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 98. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 99. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 106. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 107. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 108. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 109. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 110. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 111. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 112. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 113. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 120. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 179. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 180. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 181. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 182. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 183. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 184. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 185. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 192. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 193. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 194. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 195. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 196. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 197. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 198. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 199. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 206. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 221. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 222. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 223. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 224. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 225. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 226. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 227. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 234. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 235. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 238. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 239. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 240. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 241. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 248. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 291. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 292. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 293. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 294. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 295. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 296. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Treatment of Blastic-Phase CML market report include:
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Sandoz International GmbH
  • Lupin Limited
  • Hikma Pharmaceuticals PLC

Related Topics

Related Reports

Pharmaceuticals - Enterprise ICT - Product Image

Pharmaceuticals - Enterprise ICT

  • Report
  • 54 Pages
  • Global
From
Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028 - Product Image

Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028

  • Report
  • 286 Pages
  • North America
From
Asia-Pacific Pharmaceutical Industry Outlook 2023 - Product Image

Asia-Pacific Pharmaceutical Industry Outlook 2023

  • Report
  • 77 Pages
  • Asia Pacific
From
Pharmaceutical Automation - Global Strategic Business Report - Product Image

Pharmaceutical Automation - Global Strategic Business Report

  • Report
  • 371 Pages
  • Global
From
Leukemia Therapeutics Market by Type, Mechanism of Action, Line of Therapy, Route of Administration, Age Group, End-User - Global Forecast 2025-2030 - Product Image

Leukemia Therapeutics Market by Type, Mechanism of Action, Line of Therapy, Route of Administration, Age Group, End-User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.